Approach to developing the inventory
The COVID-END inventory of best evidence syntheses was developed and is maintained using the following approach:
- one staff member harvests evidence syntheses from the high-yield, high quality sources of evidence syntheses in our guide to COVID-19 evidence sources (which we acknowledge below) and extracts preliminary data (e.g., whether it contains a GRADE evidence profile and is a living evidence synthesis) that we use in prioritizing work flows
- each member in a pair of staff members each independently
- assesses the eligibility of each harvested synthesis (i.e., confirms it addresses a COVID-19 decision, includes a search of two or more bibliographic databases, and includes explicit criteria for selecting included studies)
- applies ‘filters’ to each evidence synthesis for all parts of the COVID-END taxonomy of decisions that are addressed by the synthesis (and resolve any differences by consensus) assesses other key features of each synthesis (e.g., type of synthesis and type of questions addressed)
- each member in a pair of staff members each independently assesses the quality of each evidence synthesis using AMSTAR (and a summary of the quality of syntheses in the database and inventory is available here)
- one staff member draws on the available data (date of last search, quality of synthesis and available GRADE profile) to identify the ‘best’ evidence synthesis (or, if there are several contenders or one contender for two or more facets of the issue, to identify the best two or more evidence syntheses), writes a ‘declarative title’ that provides decision-relevant details like the interventions or exposures examined and the certainty of available evidence, and proposes any change to the taxonomy needed to accommodate the new evidence synthesis
- a senior advisor edits the re-worded declarative title (particularly for those related to clinical management) before it is posted.
Please send suggestions for how to improve the inventory to email@example.com.
COVID-END gratefully acknowledges the ‘high-yield, high quality’ sources of evidence syntheses from which we harvest evidence syntheses to be considered for the inventory:
- U.S. Veterans’ Affairs (VA) Evidence Synthesis Program, with which COVID-END exchanges records on a weekly basis (with new evidence syntheses shared by the program and value-added content about relevant records returned by COVID-END)
- Usher Network for COVID-19 Evidence Reviews (UNCOVER), with which COVID-END exchanges records on a weekly basis (with new evidence syntheses shared by the program and value-added content about relevant records returned by COVID-END)
- Cochrane, from which COVID-END harvests Cochrane reviews
- COVID-NMA, from which COVID-END harvests updates to COVID-NMA’s living evidence syntheses on COVID-19 treatments
- Epistemonikos, from which COVID-END harvests updates to Epistemonikos’ living evidence syntheses on select topics
- PROSPERO, with which (through a grant from the UK’s National Institute of Health Research) COVID-END exchanges records on a weekly basis (with new registered protocols shared by PROSPERO and value-added content about relevant protocols returned by COVID-END)
- National Collaborating Centre for Methods and Tools, with which COVID-END exchanges records on a weekly basis (with new registered evidence syntheses shared by the program and value-added content about relevant records returned by COVID-END)
COVID-END also gratefully acknowledge the two organizations that share the information they extract from and the quality ratings they conduct as part of their decision-support activities:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.